Business
Celcuity is a clinical-stage biotechnology company focused on targeted therapies for solid tumors, led by gedatolisib.
Celcuity is a clinical-stage gedatolisib company with no revenue row, a wider loss, higher debt, and mixed insider activity.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage oncologyNote
- Revenue — N/ANote
- Operating loss — ($172.2M), widerWatch
- Net loss — ($177.0M), widerWatch
- FCF — ($153.5M)Watch
- Debt — $137.5M, +30.9%Watch
- Insiders — 1 purchase and 9 salesNote
Latest filings
- 8-K · Company announcement2026-08-26
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-07-15
- 8-K · Company announcement2026-06-08
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Celcuity Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.